SWOG S1207: Breast Cancer Trial
Choice of endocrine therapy dependent upon menopausal status and patient/physician preference
ENDOCRINE TREATMENT SHOULD BE AT LEAST 5 YEARS BUT CAN BE EXTENDED
Switching from one therapy to another is allowed
Inclusion Criteria
ü ER and/or PR positive
ü HER2 negative
ü High Risk based one of the following:
- Node negative, tumor ≥ 2cm, Oncotype RS > 25, and completed adjuvant chemo
- 1-3 pathologically positive nodes, Oncotype RS > 25, and completed adjuvant chemo
- 4+ pathologically positive nodes and completed adjuvant chemo
- 4+ pathologically positive nodes (before or after) neoadjuvant chemotherapy
ü Must have completed either adjuvant or neoadjuvant chemotherapy
ü Multifocal, multicentric, and synchronous bilateral cancer allowed
ü Lumpectomy patients MUST receive whole breast radiation
ü Patients with ≥ 4 lymph nodes positive MUST receive breast/chest wall and nodal basin RT
ü Patients with ≥ 4 lymph nodes positive MUST have axillary lymph node dissection
Exclusion Criteria
- Inflammatory breast cancer
- Metastatic breast cancer
- No prior malignancy unless disease free for at least 5 years
- Use of chronic, systemic treatment with corticosteroids or other immunosuppressive agents (topical or inhaled allowed).